NCT06101381View on ClinicalTrials.gov

CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

March 21, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Leukemia, Acute LymphoblasticLymphoma, Non-Hodgkin
Interventions
BIOLOGICAL

CART-19

The academic CART-19 consists of autologous T lymphocytes transduced with a lentiviral vector to express a second-generation chimeric antigen receptor with a single chain variable fragment (scFv) targeting the CD19 antigen conjugated with 4-1BB co-stimulatory and CD3z signaling domains.

Trial Locations (5)

13083-888

RECRUITING

Hospital de Clínicas da UNICAMP, Campinas

14048-900

RECRUITING

Ribeirao Preto School of Medicine, University of Sao Paulo, Ribeirão Preto

01308-050

RECRUITING

Hospital Sírio-Libanês, São Paulo

05403-010

RECRUITING

Hospital das Clinicas de São Paulo, São Paulo

Unknown

RECRUITING

A Beneficência Portuguesa de São Paulo, São Paulo

All Listed Sponsors
collaborator

Blood Center of Ribeirao Preto

UNKNOWN

collaborator

Hospital das Clínicas de Ribeirão Preto

OTHER

lead

University of Sao Paulo

OTHER